December 12, 2023 News by Patricia Inacio, PhD Vanda acquires rights to Ponvory for MS in US, Canada for $100M Vanda Pharmaceuticals has acquired the U.S. and Canadian rights to Ponvory (ponesimod), an oral therapy approved for relapsing types of MS, in a new deal with Actelion Pharmaceuticals. Under the terms of the agreement, Vanda paid $100 million to Actelion (now part of Janssen), the therapy’s original developer. While…
September 10, 2020 News by Marta Figueiredo, PhD #MSVirtual2020 – Ponesimod Superior to Aubagio in Delaying Disability Progression in Relapsing MS, Trial Data Show Janssen Pharmaceuticals’ investigational oral therapy ponesimod is superior to Sanofi’s Aubagio (teriflunomide) in delaying disability progression in adults with relapsing multiple sclerosis (MS), according to exploratory analyses of OPTIMUM clinical trial data. These and other findings from Janssen’s MS research program, including on the health…
December 10, 2019 News by Ana Pena PhD Astrocytes in Brain Seen as Possible Trigger of Progressive MS via Processes of Metabolism Processes related to metabolism in brain cells known as astrocytes may be at the origin of multiple sclerosis (MS), particularly underlying the inflammation and damage to the nervous system seen in progressive disease, a study in mice found.
September 18, 2019 News by Ana Pena PhD #ECTRIMS2019 — Ponesimod Superior to Aubagio in Relapsing MS, OPTIMUM Trial Shows Actelion‘s ponesimod, an investigational oral treatment, is superior to Sanofi‘s Aubagio (teriflunomide) in lessening the frequency of relapses and easing fatigue symptoms in adults with active, relapsing multiple sclerosis (MS), results of the OPTIMUM trial show. These data will lay the ground for submissions…
July 30, 2019 News by Ana Pena PhD Ponesimod Fares Well in Phase 3 Trial for Relapsing MS, Janssen Announces Janssen has announced positive, top-line results from its Phase 3 OPTIMUM study, testing the effectiveness and safety of ponesimod tablets, compared to Sanofi‘s Aubagio (teriflunomide), in adults with relapsing forms of multiple sclerosis (MS). The study met its primary goal — a reduction in the…
November 8, 2017 News by Patricia Silva, PhD Global Phase 3 Trial of Oral Ponesimod Plus Tecfidera Enrolling Relapsing MS Patients Actelion is recruiting about 600 relapsing multiple sclerosis (MS) patients to a Phase 3 trial testing the addition of oral ponesimod to Tecfidera (dimethyl fumarate) in people who continue experiencing relapses while on the treatment. Ponesimod works in a similar way to Novartis’ Gilenya (fingolimod) — making immune…
October 3, 2016 News by Patricia Silva, PhD Phase 3 Study to Test Oral Combination, Tecfidera and Ponesimod, to Treat Relapsing MS Actelion announced that it will investigate the therapeutic potential of a new, oral combination therapy with ponesimod and Tecfidera (dimethyl fumarate) as a treatment for relapsing multiple sclerosis (RMS). The Phase 3 clinical study, being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA), aims to find…
